Is Johnson & Johnson Stock Outperforming the Dow? Johnson & Johnson has outperformed the Dow Jones over the past year, and analysts remain moderately optimistic about the stock’s outlook. Barchart · May 28
The $4 Billion Reason Eli Lilly Stock Is Up Today Eli Lilly shares inch higher as the company announced three acquisitions for nearly $4 billion. Here’s why each of the three vaccine makers it’s buying is bullish for LLY stock. Barchart · May 27
MarketBeat Week in Review – 05/18 - 05/22 Stocks were up sharply to end the week as NVIDIA’s forward guidance showed tangible demand to support AI infrastructure and overshadowed mixed retail reports MarketBeat · May 23
From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook Eli Lilly just got more good news, posting promising results for its oral GLP-1 as the firm looks to unlock new sources of demand. MarketBeat · May 20
What the FDA's Latest Proposal Means for Lilly, Novo, and Hims The FDA's latest proposal would be a win for Eli Lilly and Novo Nordisk, while Hims & Hers Health would also garner indirect benefits. MarketBeat · May 7
Do Wall Street Analysts Like Eli Lilly Stock? While Eli Lilly has slightly lagged behind the SPX over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects. Barchart · May 6
Lilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanent Eli Lilly's 2026 is off to a great start, with massive earnings and revenue beats and exciting updates about its latest GLP-1, Foundayo. MarketBeat · May 1
Eli Lilly Stock Popped on Earnings. America Can’t Get Enough of Its GLP-1s. Eli Lilly stock jumps on strong Q1 performance numbers, with its GLP-1s leading the chart. Barchart · May 1
GLP-1 Sales Continue to Lift Eli Lilly. Does That Make LLY Stock a Buy? Eli Lilly stock rallies as GLP-1 sales drive a 56% year-on-year increase in Q1 revenue. Jim Cramer recommends buying LLY shares as the weight-loss addressable market is truly huge. Barchart · Apr 30
Should You Buy the Dip in Eli Lilly Stock Today? Eli Lilly shares sink as data shows Foundayo trailing Novo’s oral Wegovy. But there’s reason to consider buying LLY shares on the dip today. Barchart · Apr 27
3 Giant Dividend Stocks Raising Payouts With Yields Up to 4% Johnson & Johnson, Albertsons, and Procter & Gamble have each raised their dividends, lifting yields to between 2.3% and 4% despite mixed performance in 2025. MarketBeat · Apr 20
What to Expect From Eli Lilly's Next Quarterly Earnings Report Eli Lilly is approaching its first-quarter earnings release this month, and Wall Street is forecasting a triple-digit percentage rise in earnings. Barchart · Apr 9
The Next Big AI Winner Might Not Be a Tech Company Lilly’s AI push shows how non-tech firms can dominate the next wave. Barchart · Apr 4
Eli Lilly Pops on GLP-1 Pill Approval. Should You Buy LLY Stock Here? Eli Lilly stock rallies as the firm’s oral weight-loss pill, Foundayo, secures FDA approval. Options pricing suggests LLY shares will rip higher over the next three months. Barchart · Apr 1
Barchart · Mar 31 Eli Lilly Is Bringing AI-Developed Drugs to Market. Should You Buy LLY Stock to Profit? Eli Lilly has expanded its partnership with Insilico Medicine to bring AI developed medicine into global market.
MarketBeat · Mar 18 Members of Congress Bought These 5 Stocks—Should You? Five stocks recently traded by members of Congress—from AI defense to GLP-1 leaders—could offer clues for investors building their watchlists
MarketBeat · Mar 15 3 Stocks That Could Be Next to Announce a Stock Split Stock splits often follow strong growth. Here are three high-priced stocks that could be candidates for a stock split in 2026
MarketBeat · Mar 15 Eli Lilly’s Employer Push Could Unlock New GLP-1 Demand Eli Lilly is launching Employer Connect to expand Zepbound access while its oral GLP-1 orforglipron just topped Novo Nordisk's Rybelsus in a head-to-head trial.
MarketBeat · Mar 13 The Real Reason Eli Lilly Is Pouring $3 Billion Into China Eli Lilly's major investment in China's manufacturing capacity is a strategic move to secure its supply chain and capture a vast, untapped growth market.
MarketBeat · Mar 12 Megatrends Still Matter: 3 Growth Stocks for the Next 10 Years Discover three megatrend stocks positioned for the next decade of growth as AI, healthcare innovation, and clean energy reshape the global economy
Barchart · Mar 4 Is Moderna Stock Outperforming the Dow? Moderna has outperformed the Dow over the past year, yet Wall Street analysts maintain a cautious outlook on the stock’s prospects.
Barchart · Feb 27 Is Bristol-Myers Squibb Stock Underperforming the Nasdaq? Though Bristol-Myers Squibb has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.
MarketBeat · Feb 26 Viking Therapeutics: The High-Stakes Weight Loss Contender Viking Therapeutics is positioning itself as a contender in the obesity market with a dual strategy of rapid clinical progress and commercial preparation.
Barchart · Feb 24 Is Johnson & Johnson Stock Outperforming the Nasdaq? Though Johnson & Johnson has outperformed the broader Nasdaq Composite over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.
Barchart · Feb 24 Is Eli Lilly Stock Underperforming the S&P 500? Eli Lilly has recently trailed the S&P 500 Index, though analysts remain confident in its longer-term trajectory.